The CodeBreak 101 study showed that the objective response rate (ORR) of Sotorasib combined with panitumumab achieved 27% in patients with advanced/metastatic CRC with a KRAS G12C mutation and the disease control rate (DCR) reached 81%. This evidence concerns the gene KRAS and colorectal carcinoma.